DK2420496T3 - Antiepileptisk, hypocholesterolæmisk og neurobeskyttende forbindelse - Google Patents

Antiepileptisk, hypocholesterolæmisk og neurobeskyttende forbindelse Download PDF

Info

Publication number
DK2420496T3
DK2420496T3 DK10720187T DK10720187T DK2420496T3 DK 2420496 T3 DK2420496 T3 DK 2420496T3 DK 10720187 T DK10720187 T DK 10720187T DK 10720187 T DK10720187 T DK 10720187T DK 2420496 T3 DK2420496 T3 DK 2420496T3
Authority
DK
Denmark
Prior art keywords
nst0037
compound
animals
pbs
days
Prior art date
Application number
DK10720187T
Other languages
English (en)
Inventor
Muñoz Javier Santos Burgos
Fondevila José Luis Adrio
Martín Maria Del Carmen Ramos
Ávila Saleta Sierra
Sánchez Juan María Alfaro
Moreno Carlos Ramírez
García Sonia Campoy
Alvarez Javier Velasco
Sánchez Ángel Rumbero
Original Assignee
Neuron Biopharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Biopharma Sa filed Critical Neuron Biopharma Sa
Application granted granted Critical
Publication of DK2420496T3 publication Critical patent/DK2420496T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)

Claims (6)

1. Forbindelse med formel (I)
dens hydroxysyreform, farmaceutisk acceptable salte af hydroxysyren og farmaceutisk acceptable solvater af forbindelsen og af dens hydroxysyreform.
2. Farmaceutisk præparat, som omfatter en forbindelse med formel (I) ifølge krav 1 og/eller dens hydroxysyreform og/eller et farmaceutisk acceptabelt salt af hydroxysyren og/eller et farmaceutisk acceptabelt solvat af forbindelsen eller af dens hydroxysyreform og mindst én farmaceutisk acceptabel adjuvans, bærer og/eller vehikel.
3. Forbindelse med formel (I) ifølge krav 1, dens hydroxysyreform eller et farmaceutisk acceptabelt salt af hydroxysyren og/eller et farmaceutisk acceptabelt solvat af forbindelsen eller af dens hydroxysyreform til anvendelse som lægemiddel.
4. Forbindelse med formel (I) ifølge krav 1, dens hydroxysyreform eller et farmaceutisk acceptabelt salt af hydroxysyren og/eller et farmaceutisk acceptabelt solvat af forbindelsen eller af dens hydroxysyreform til anvendelse til forebyggelse og/eller behandling af: neurodegenerative sygdomme, kognitiv svækkelse, aldersrelaterede patologiske processer, som angår en hvilken som helst aldersrelateret begivenhed eller kombination af begivenheder, der forårsager tab af cellelevedygtighed i nervevævet eller cellesensibilisering af nervevævet, tab af cellefunktion og/eller tab af antallet af celler; og progeria, eller epilepsi, epileptiske anfald og krampeanfald.
5. Forbindelse med formel (I), dens hydroxysyreform eller et farmaceutisk acceptabelt salt af hydroxysyren og/eller et farmaceutisk acceptabelt solvat af forbindelsen eller af dens hydroxysyreform ifølge krav 4, hvor de neurodegenerative sygdomme er: Alzhei-mers sygdom, Huntingtons sygdom, Parkinsons sygdom, amyotrofisk lateral sklerose (ALS) eller multipel sklerose.
6. Anvendelse af en forbindelse med formel (I) ifølge krav 1, af dens hydroxysyreform, af et farmaceutisk acceptabelt salt af hydroxysyren og/eller af et farmaceutisk acceptabelt solvat af forbindelsen eller af dens hydroxysyreform til fremstilling af et lægemiddel til forebyggelse og/eller behandling af: neurodegenerative sygdomme, kognitiv svækkelse, aldersrelaterede patologiske processer, som angår en hvilken som helst aldersrelateret begivenhed eller kombination af begivenheder, der forårsager tab af cellelevedygtighed i nervevævet eller cellesensibilisering af nervevævet, tab af cellefunktion og/eller tab af antallet af celler; og progeria, eller epilepsi, epileptiske anfald og krampeanfald.
DK10720187T 2009-04-16 2010-04-16 Antiepileptisk, hypocholesterolæmisk og neurobeskyttende forbindelse DK2420496T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382051A EP2241561A1 (en) 2009-04-16 2009-04-16 Neuroprotective, hypocholesterolemic and antiepileptic compound
PCT/ES2010/070234 WO2010119161A2 (es) 2009-04-16 2010-04-16 Compuesto neuroprotector, hipocolesterolémico y antiepiléptico

Publications (1)

Publication Number Publication Date
DK2420496T3 true DK2420496T3 (da) 2015-03-30

Family

ID=40972871

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10720187T DK2420496T3 (da) 2009-04-16 2010-04-16 Antiepileptisk, hypocholesterolæmisk og neurobeskyttende forbindelse

Country Status (14)

Country Link
US (2) US20120095091A1 (da)
EP (2) EP2241561A1 (da)
JP (1) JP5759448B2 (da)
CN (1) CN102428078A (da)
AU (1) AU2010238429B2 (da)
BR (1) BRPI1015173A2 (da)
CA (1) CA2758852A1 (da)
DK (1) DK2420496T3 (da)
ES (1) ES2533092T3 (da)
IL (1) IL215858A (da)
MX (1) MX341254B (da)
PL (1) PL2420496T3 (da)
PT (1) PT2420496E (da)
WO (1) WO2010119161A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2418684B1 (es) * 2012-02-07 2014-06-05 Neuron Biopharma, S.A. Análogos formilados de xantocilinas como neuroprotectores
CN104955330A (zh) * 2012-09-13 2015-09-30 Cba制药有限公司 粉防己碱药物制剂及方法
KR20150142691A (ko) 2013-03-15 2015-12-22 씨비에이 파마, 인크. 테트란드린 패밀리 제약 제제 및 방법
ES2524647B1 (es) 2013-06-06 2015-09-15 Neuron Bio, S.A. Compuestos neuroprotectores, antiinflamatorios y antiepilépticos
JP7412177B2 (ja) * 2018-02-19 2024-01-12 國子 草間 バレロラクトン（Ｖａｌｅｒｏｌａｃｔｏｎｅ）系新規化合物、及び、医薬
CN114515341A (zh) * 2022-03-22 2022-05-20 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) Dhcr24基因在制备治疗神经退行性疾病药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4293496A (en) * 1980-02-04 1981-10-06 Merck & Co., Inc. 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones
AU548996B2 (en) * 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4866090A (en) 1988-01-07 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
AR013445A1 (es) * 1997-08-28 2000-12-27 Novartis Ag Antagonistas de lfa-1
WO2000047196A2 (en) * 1999-02-11 2000-08-17 Hollis-Eden Pharmaceuticals, Inc. Use of statins for treating viral infections
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders

Also Published As

Publication number Publication date
MX2011010978A (es) 2012-01-19
MX341254B (es) 2016-08-12
PL2420496T3 (pl) 2015-06-30
WO2010119161A3 (es) 2010-12-23
CN102428078A (zh) 2012-04-25
JP5759448B2 (ja) 2015-08-05
EP2241561A1 (en) 2010-10-20
ES2533092T3 (es) 2015-04-07
CA2758852A1 (en) 2010-10-21
JP2012524047A (ja) 2012-10-11
EP2420496B1 (en) 2014-12-24
PT2420496E (pt) 2015-03-26
EP2420496A2 (en) 2012-02-22
AU2010238429B2 (en) 2016-05-26
US20120095091A1 (en) 2012-04-19
WO2010119161A2 (es) 2010-10-21
US20140309295A1 (en) 2014-10-16
AU2010238429A1 (en) 2011-11-10
IL215858A (en) 2016-11-30
IL215858A0 (en) 2012-01-31
BRPI1015173A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
US20140309295A1 (en) Antiepileptic, hypocholesterolemic and neuroprotective compound
Heiseke et al. Autophagy, prion infection and their mutual interactions
Pinton et al. p, p′-Methoxyl-diphenyl diselenide protects against amyloid-β induced cytotoxicity in vitro and improves memory deficits in vivo
Biondi Prescription of lipophilic statins to Alzheimer’s disease patients: some controversies to consider
US8927599B2 (en) Use of statins as anticonvulsants, antiepileptics and neuroprotectors
JP2022522299A (ja) 神経系疾患の予防または治療用薬学的組成物
EP2628737A1 (en) Hypocholesterolemic, anti-inflammatory and antiepileptic neuroprotective compound
CN105111195B (zh) 他克林-联苯双酯杂合物、其制备方法及应用
EP3006435A1 (en) Anti-inflammatory and antiepileptic neuroprotective statin compounds
JP5919208B2 (ja) 脳保護剤
JP2011046734A (ja) セマフォリン阻害剤としての新規化合物
KR100878838B1 (ko) 베타아밀로이드에 의한 세포 독성 및 기억력 손상 억제용 약학적 조성물, 및 건강기능식품
KR102050063B1 (ko) 꽃송이버섯 추출물을 포함하는 이상지질혈증 관련 질환 예방 또는 치료용 조성물
JP7367959B2 (ja) 脳由来神経栄養因子産生促進剤、神経成長因子産生促進剤、酸化ストレス抑制剤及びそれらの使用
EP2404599A1 (en) Neuroprotective compounds
JP2021520412A (ja) タンパク質ミスフォールディング疾患のための療法
AU2006299378A1 (en) The genetic risk assessment in heart failure: impact of genetic variation of aldosterone synthase promoter polymorphism